In beginning the first phase 3 clinical trial to examine a vaccine candidate for the coronavirus disease 2019 (COVID-19), Moderna Inc announced that the Trump administration increased funding to expand the trial to 30,000 US participants; employers have considered and some have made it a requirement for employees to sign a waiver to not sue the organization if they are infected by COVID-19 or suffered any injury while working; study finds 1 flu shot can reduce the risk for Alzheimer disease by 17% and 1 pneumonia vaccine before age 75 can reduce the risk by 25%.
In beginning the first phase 3 clinical trial to examine a vaccine candidate for the coronavirus disease 2019 (COVID-19) today, Moderna Inc announced that the Trump administration increased funding by $472 million to expand the trial to 30,000 US participants. POLITICO reported that the investment was made by the Biomedical Advanced Research and Development Authority (BARDA), which brings the total investment from BARDA to $955 million. The article noted that the Trump administration is hopeful that initial vaccines can be distributed in as little as 3 months.
According to Kaiser Health News, as employees nationwide return to the workplace amid the COVID-19 pandemic, many employers have considered, and some have made it a requirement, for employees to sign a waiver to not sue the organization if they are infected or suffered any injury while working. While some employers have made these waivers mandatory, lawyers cited in the article say that state laws do not allow employers to force employees to sign away their right to pursue workers’ compensation claims.
According to a pair of studies presented today at this year’s virtual Alzheimer Association International Conference, participants who received at least 1 flu shot were found to have a 17% reduced risk for Alzheimer disease, with those who get a pneumonia vaccine before age 75 also exhibiting a reduction in risk by 25%. Researchers caution that the amount of benefit from flu vaccination may vary based on the demographics of the cohort, reported NPR. There was no added benefit from being dually vaccinated for the flu and pneumonia.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Key Issues Influencing 2022 Employer Health Care Strategy and Plan Design
August 31st 2021On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.
Listen
Retaining Health Care Workers Starts With Insights on “How We Can Stop Breaking Them”
March 2nd 2024Friday's keynote speaker, Katherine A. Meese, PhD, addressed the conference theme of workforce support at the Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit.
Read More
Lowering Cardiometabolic Drug Costs May Improve Diabetes Health Outcomes
February 9th 2024Patients enrolled in a preventive drug list (PDL) benefit saw an 8.4% reduction in acute, preventable diabetes complication days, and PDL members residing in lower-income areas saw a 10.2% decrease compared with control members.
Read More